Sheng Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Sheng Zhou has a total of 155 co-authors. Here are the top co-authors by number of shared publications:
Feng Bi
7 shared publications- Hongwei Xia
Department of Ultrasound, GongLi Hospital of Shanghai Pu Dong New District, Shanghai, 200135, China
7 shared publications - Huanji Xu
Department of Medical Oncology, Cancer Center and Laboratory of Molecular Targeted Therapy in Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China
7 shared publications Qiulin Tang
7 shared publicationsBrian P. Sorrentino
Division of Experimental Hematology, Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN, USA
6 shared publicationsSoghra Fatima
Division of Experimental Hematology, Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN, USA
4 shared publications
Latest Publications
- Open Access
- 12 May 2026
- Published by Elsevier in Cytotherapy
- Vol. 28 (8) , 102907
Successful autologous T cell apheresis in pediatric patients with hematologic malignancies, solid tumors, and brain tumors
- 12 May 2026
- Published by Elsevier in Cytotherapy
- Vol. 28 (8) , 102907
Open AccessSuccessful autologous T cell apheresis in pediatric patients with hematologic malignancies, solid tumors, and brain tumors
- Open Access
- 6 October 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (40) , eadg9959
Integrome signatures of lentiviral gene therapy for SCID-X1 patients
Lentiviral vector (LV)–based gene therapy holds promise for a broad range of diseases. Analyzing more than 280,000 vector integration sites (VISs) in 273 samples from 10 patients with X-linked severe combined immunodeficiency (SCID-X1), we discovered shared LV integrome signatures in 9 of 10 patients in relation to the genomics, epigenomics, and 3D structure of the human genome. VISs were enriched in the nuclear subcompartment A1 and integrated into super-enhancers close to nuclear pore complexes. These signatures were validated in T cells transduced with an LV encoding a CD19-specific chimeric antigen receptor. Intriguingly, the one patient whose VISs deviated from the identified integrome signatures had a distinct clinical course. Comparison of LV and gamma retrovirus integromes regarding their 3D genome signatures identified differences that might explain the lower risk of insertional mutagenesis in LV-based gene therapy. Our findings suggest that LV integrome signatures, shaped by common features such as genome organization, may affect the efficacy of LV-based cellular therapies.
- 6 October 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (40) , eadg9959
Open AccessIntegrome signatures of lentiviral gene therapy for SCID-X1 patients
Lentiviral vector (LV)–based gene therapy holds promise for a broad range of diseases. Analyzing more than 280,000 vector integration sites (VISs) in 273 samples from 10 patients with X-linked severe combined immunodeficiency (SCID-X1), we discovered shared LV integrome signatures in 9 of 10 patients in relation to the genomics, epigenomics, and 3D structure of the human genome. VISs were enriched in the nuclear subcompartment A1 and integrated into super-enhancers close to nuclear pore complexes. These signatures were validated in T cells transduced with an LV encoding a CD19-specific chimeric antigen receptor. Intriguingly, the one patient whose VISs deviated from the identified integrome signatures had a distinct clinical course. Comparison of LV and gamma retrovirus integromes regarding their 3D genome signatures identified differences that might explain the lower risk of insertional mutagenesis in LV-based gene therapy. Our findings suggest that LV integrome signatures, shaped by common features such as genome organization, may affect the efficacy of LV-based cellular therapies.
- 9 September 2023
- Published by Elsevier in Cytotherapy
- Vol. 25 (11) , 1149-1154
Preparation of cryopreserved chimeric antigen receptor T cells for the locoreogional delivery to the neural axis
- 9 September 2023
- Published by Elsevier in Cytotherapy
- Vol. 25 (11) , 1149-1154
Preparation of cryopreserved chimeric antigen receptor T cells for the locoreogional delivery to the neural axis
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from Dipyridamole Enhances the Cytotoxicities of Trametinib against Colon Cancer Cells through Combined Targeting of HMGCS1 and MEK Pathway
Simvastatin increased the expression of pERK through up-regulating the HMGCS1.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Dipyridamole Enhances the Cytotoxicities of Trametinib against Colon Cancer Cells through Combined Targeting of HMGCS1 and MEK Pathway
Simvastatin increased the expression of pERK through up-regulating the HMGCS1.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from Dipyridamole Enhances the Cytotoxicities of Trametinib against Colon Cancer Cells through Combined Targeting of HMGCS1 and MEK Pathway
HMGCS1 regulates the migration of colon cancer cells.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Dipyridamole Enhances the Cytotoxicities of Trametinib against Colon Cancer Cells through Combined Targeting of HMGCS1 and MEK Pathway
HMGCS1 regulates the migration of colon cancer cells.